C1-esterase inhibitor

Phase 3Completed

2 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Hereditary Angioedema Types I and II

Conditions

Hereditary Angioedema Types I and II

Trial Timeline

Dec 31, 2014 → Sep 21, 2017

NCT ID

NCT02316353

About C1-esterase inhibitor

C1-esterase inhibitor is a phase 3 stage product being developed by CSL for Hereditary Angioedema Types I and II. The current trial status is completed. This product is registered under clinical trial identifier NCT02316353. Target conditions include Hereditary Angioedema Types I and II.

What happened to similar drugs?

3 of 20 similar drugs in Hereditary Angioedema Types I and II were approved

Approved (3) Terminated (0) Active (17)

✅Berinert, lyophilizate for IV application containing 500 IU C1-INH to be reconstituted with 10 mL water for injectionCSLApproved

✅GaradacimabCSLApproved

✅IdebenoneSanthera PharmaceuticalsApproved

🔄KVD900 600 mg + KVD900 300 mgKalVista PharmaceuticalsPhase 3

🔄Placebo + KVD900 600 mg + KVD900 300 mgKalVista PharmaceuticalsPhase 3

🔄KVD900 150 mg + KVD900 300 mg + KVD900 600 mgKalVista PharmaceuticalsPhase 3

🔄KVD900 600 mg + Drug: KVD900 300 mgKalVista PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02316353	Phase 3	Completed	Dec 31, 2014	Sep 21, 2017	Hereditary Angioedema Types I and II
NCT00748202	Phase 3	Completed	Sep 1, 2008	Dec 1, 2010	Hereditary Angioedema

Competing Products

20 competing products in Hereditary Angioedema Types I and II

See all competitors

Product	Company	Stage	Hype Score
KVD900	KalVista Pharmaceuticals	Phase 2	29
KVD824 + Placebo to KVD824	KalVista Pharmaceuticals	Phase 1	23
KVD900 600 mg + KVD900 300 mg	KalVista Pharmaceuticals	Phase 3	38
Sebetralstat	KalVista Pharmaceuticals	Pre-clinical	20
KVD900 + Placebo to KVD900	KalVista Pharmaceuticals	Phase 1	23
Sebetralstat	KalVista Pharmaceuticals	Pre-clinical	24
Placebo + KVD900 600 mg + KVD900 300 mg	KalVista Pharmaceuticals	Phase 3	34
KVD824 Prototype 1 modified-release tablet + KVD824 Prototype 2 modified-release tablet + KVD824 Immediate-Release Capsule + Placebo to KVD824 Prototype 1 + KVD824 Prototype 3 modified-release tablet	KalVista Pharmaceuticals	Phase 1	23
KVD900 150 mg + KVD900 300 mg + KVD900 600 mg	KalVista Pharmaceuticals	Phase 3	34
KVD824 + Placebo to KVD824	KalVista Pharmaceuticals	Phase 2	21
KVD900 600 mg + Drug: KVD900 300 mg	KalVista Pharmaceuticals	Phase 3	38
Deferasirox FCT	Novartis	Phase 2	27
Canakinumab + Placebo	Novartis	Phase 3	40
Ilaris	Novartis	Pre-clinical	33
Standard of Care for Haemophilia A	Roche	Pre-clinical	26
Emicizumab	Roche	Phase 3	40
Tafamidis	Pfizer	Pre-clinical	26
tafamidis	Pfizer	Pre-clinical	26
Nitisinone	Swedish Orphan Biovitrum	Pre-clinical	26
Nitisinone	Swedish Orphan Biovitrum	Phase 1	29